Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
NCT03900468 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
Conditions Studied
Interventions
- DEVICE Activa™ PC and Percept™ PC Neurostimulation Systems
Study Locations (13)
California
- University of California Los Angeles (UCLA) — Los Angeles
- University of California San Francisco UCSF Medical Center — San Francisco
- Stanford Hospital & Clinics — Stanford
Ohio
- Cleveland Clinic — Cleveland
- The Ohio State University — Columbus
Georgia
- Emory University Hospital — Atlanta
Illinois
- Rush University Medical Center — Chicago
Indiana
- Indiana University Health Neuroscience Center — Indianapolis
Kansas
- University of Kansas Medical Center — Kansas City
Massachusetts
- Massachusetts General Hospital — Boston
Minnesota
- Mayo Clinic (Rochester MN) — Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2020-03-05 |
| Est. Completion | 2026-03-27 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03900468
The ClinicalTrials.gov registry entry for NCT03900468 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedtronicNeuro, which has 14 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention — of which Activa™ PC and Percept™ PC Neurostimulation Systems is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03900468 reports 13 study locations spanning 10 distinct geographic areas — top geographies include California, Ohio, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03900468 about?
NCT03900468 is a clinical study titled "Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)". The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
What is the current status of trial NCT03900468?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2020-03-05. Estimated completion is 2026-03-27.
What conditions does trial NCT03900468 study?
This clinical trial studies the following conditions: Epilepsy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03900468?
The interventions under investigation include: Activa™ PC and Percept™ PC Neurostimulation Systems (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03900468?
This trial is sponsored by MedtronicNeuro, which has 14 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03900468 being conducted?
This trial has 13 study locations across California, Georgia, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.